The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (135)
August 15, 2011
- Maurer's Healthcare Insight (134)
August 1, 2011
- Maurer's Healthcare Insight (133)
July 11, 2011
- Maurer's Healthcare Insight (132)
May 30, 2011
- Maurer's Healthcare Insight (131)
April 18, 2011
- Maurer's Healthcare Insight (130)
January 24, 2011
- Maurer's Healthcare Insight (129)
January 3, 2011
- Maurer's Healthcare Insight (128)
December 13, 2010
- Maurer's Healthcare Insight (127)
November 29, 2010
- Maurer's Healthcare Insight (126)
November 8, 2010
- Maurer's Healthcare Insight (125)
October 25, 2010
- Maurer's Healthcare Insight (124)
October 11, 2010
- Maurer's Healthcare Insight (123)
July 12, 2010
- Maurer's Healthcare Insight (122)
May 31, 2010
- Maurer's Healthcare Insight (121)
May 3, 2010
- Maurer's Healthcare Insight (120)
April 12, 2010
- Maurer's Healthcare Insight (119)
March 1, 2010
- Maurer's Healthcare Insight (118)
January 4, 2010
- Maurer's Healthcare Insight (117)
December 14, 2009
- Maurer's Healthcare Insight (116)
November 30, 2009
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…